CN113698453B - Antarctic krill hypolipidemic peptide and application thereof in treating hyperlipidemia - Google Patents
Antarctic krill hypolipidemic peptide and application thereof in treating hyperlipidemia Download PDFInfo
- Publication number
- CN113698453B CN113698453B CN202111011432.9A CN202111011432A CN113698453B CN 113698453 B CN113698453 B CN 113698453B CN 202111011432 A CN202111011432 A CN 202111011432A CN 113698453 B CN113698453 B CN 113698453B
- Authority
- CN
- China
- Prior art keywords
- peptide
- hypolipidemic
- antarctic krill
- hyperlipidemia
- medicament
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 63
- 230000000055 hyoplipidemic effect Effects 0.000 title claims abstract description 62
- 241000239366 Euphausiacea Species 0.000 title claims abstract description 41
- 208000031226 Hyperlipidaemia Diseases 0.000 title claims abstract description 34
- 239000003814 drug Substances 0.000 claims abstract description 27
- 125000003275 alpha amino acid group Chemical group 0.000 claims abstract 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims description 29
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 claims description 28
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 claims description 28
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 claims description 28
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 claims description 28
- 239000005642 Oleic acid Substances 0.000 claims description 28
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 claims description 28
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 claims description 28
- 241000239370 Euphausia superba Species 0.000 claims description 20
- 150000002632 lipids Chemical class 0.000 claims description 17
- 108010028554 LDL Cholesterol Proteins 0.000 claims description 14
- 235000012000 cholesterol Nutrition 0.000 claims description 14
- 108010023302 HDL Cholesterol Proteins 0.000 claims description 13
- 210000002966 serum Anatomy 0.000 claims description 12
- 238000002360 preparation method Methods 0.000 claims description 11
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 claims description 11
- 230000006872 improvement Effects 0.000 claims description 5
- 238000009825 accumulation Methods 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 2
- 239000008297 liquid dosage form Substances 0.000 claims description 2
- 239000008176 lyophilized powder Substances 0.000 claims description 2
- 238000009098 adjuvant therapy Methods 0.000 claims 1
- 239000004615 ingredient Substances 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 27
- 235000013305 food Nutrition 0.000 abstract description 8
- 102000004196 processed proteins & peptides Human genes 0.000 abstract description 8
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 abstract description 6
- 231100000331 toxic Toxicity 0.000 abstract description 6
- 230000002588 toxic effect Effects 0.000 abstract description 6
- 150000001875 compounds Chemical class 0.000 abstract description 4
- 230000036541 health Effects 0.000 abstract description 3
- 150000001413 amino acids Chemical class 0.000 description 15
- 239000000243 solution Substances 0.000 description 15
- 150000003626 triacylglycerols Chemical class 0.000 description 15
- 241000700159 Rattus Species 0.000 description 14
- 238000000034 method Methods 0.000 description 14
- 239000011347 resin Substances 0.000 description 14
- 229920005989 resin Polymers 0.000 description 14
- 230000006372 lipid accumulation Effects 0.000 description 11
- 238000004007 reversed phase HPLC Methods 0.000 description 11
- 229940088598 enzyme Drugs 0.000 description 9
- 239000000047 product Substances 0.000 description 9
- 102000004190 Enzymes Human genes 0.000 description 8
- 108090000790 Enzymes Proteins 0.000 description 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 8
- 239000012154 double-distilled water Substances 0.000 description 8
- 101710172465 Nucleoside triphosphatase I Proteins 0.000 description 7
- 238000005227 gel permeation chromatography Methods 0.000 description 7
- 239000007788 liquid Substances 0.000 description 7
- 239000000843 powder Substances 0.000 description 7
- 239000000523 sample Substances 0.000 description 7
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- 239000000463 material Substances 0.000 description 6
- 108010038807 Oligopeptides Proteins 0.000 description 5
- 102000015636 Oligopeptides Human genes 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 238000012986 modification Methods 0.000 description 5
- 230000004048 modification Effects 0.000 description 5
- 238000000746 purification Methods 0.000 description 5
- 238000011160 research Methods 0.000 description 5
- 241000238557 Decapoda Species 0.000 description 4
- 235000001014 amino acid Nutrition 0.000 description 4
- 229940024606 amino acid Drugs 0.000 description 4
- 238000001914 filtration Methods 0.000 description 4
- 238000000108 ultra-filtration Methods 0.000 description 4
- 238000005406 washing Methods 0.000 description 4
- 108090000145 Bacillolysin Proteins 0.000 description 3
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 3
- 208000017170 Lipid metabolism disease Diseases 0.000 description 3
- 102000035092 Neutral proteases Human genes 0.000 description 3
- 108091005507 Neutral proteases Proteins 0.000 description 3
- 102000057297 Pepsin A Human genes 0.000 description 3
- 108090000284 Pepsin A Proteins 0.000 description 3
- 230000002159 abnormal effect Effects 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 238000004440 column chromatography Methods 0.000 description 3
- XELZGAJCZANUQH-UHFFFAOYSA-N methyl 1-acetylthieno[3,2-c]pyrazole-5-carboxylate Chemical compound CC(=O)N1N=CC2=C1C=C(C(=O)OC)S2 XELZGAJCZANUQH-UHFFFAOYSA-N 0.000 description 3
- 229940111202 pepsin Drugs 0.000 description 3
- 229920001184 polypeptide Polymers 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 235000018102 proteins Nutrition 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 239000002994 raw material Substances 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 108010004103 Chylomicrons Proteins 0.000 description 2
- 208000032928 Dyslipidaemia Diseases 0.000 description 2
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 2
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 2
- 101710196562 RNA helicase NPH-II Proteins 0.000 description 2
- 108010069201 VLDL Cholesterol Proteins 0.000 description 2
- 230000035508 accumulation Effects 0.000 description 2
- 210000004712 air sac Anatomy 0.000 description 2
- 239000007853 buffer solution Substances 0.000 description 2
- 238000004140 cleaning Methods 0.000 description 2
- 238000005238 degreasing Methods 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 238000004821 distillation Methods 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 238000010828 elution Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 230000007071 enzymatic hydrolysis Effects 0.000 description 2
- 238000006047 enzymatic hydrolysis reaction Methods 0.000 description 2
- 235000019441 ethanol Nutrition 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 230000000415 inactivating effect Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 238000001819 mass spectrum Methods 0.000 description 2
- 235000012054 meals Nutrition 0.000 description 2
- 235000013372 meat Nutrition 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 230000017854 proteolysis Effects 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 241000251468 Actinopterygii Species 0.000 description 1
- 101800000068 Antioxidant peptide Proteins 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 241000238366 Cephalopoda Species 0.000 description 1
- 208000004930 Fatty Liver Diseases 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 108010010234 HDL Lipoproteins Proteins 0.000 description 1
- 102000015779 HDL Lipoproteins Human genes 0.000 description 1
- 206010019708 Hepatic steatosis Diseases 0.000 description 1
- 201000001431 Hyperuricemia Diseases 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- 208000002720 Malnutrition Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000961010 Miichthys miiuy Species 0.000 description 1
- 235000010676 Ocimum basilicum Nutrition 0.000 description 1
- 240000007926 Ocimum gratissimum Species 0.000 description 1
- 206010033645 Pancreatitis Diseases 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 108010009736 Protein Hydrolysates Proteins 0.000 description 1
- 230000010757 Reduction Activity Effects 0.000 description 1
- 206010039020 Rhabdomyolysis Diseases 0.000 description 1
- RYMZZMVNJRMUDD-UHFFFAOYSA-N SJ000286063 Natural products C12C(OC(=O)C(C)(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 RYMZZMVNJRMUDD-UHFFFAOYSA-N 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 238000007792 addition Methods 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- -1 ammonium glycoside Chemical class 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000003276 anti-hypertensive effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 229960005110 cerivastatin Drugs 0.000 description 1
- SEERZIQQUAZTOL-ANMDKAQQSA-N cerivastatin Chemical compound COCC1=C(C(C)C)N=C(C(C)C)C(\C=C\[C@@H](O)C[C@@H](O)CC(O)=O)=C1C1=CC=C(F)C=C1 SEERZIQQUAZTOL-ANMDKAQQSA-N 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000007882 cirrhosis Effects 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 230000009849 deactivation Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 208000010706 fatty liver disease Diseases 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 230000037356 lipid metabolism Effects 0.000 description 1
- 108010022197 lipoprotein cholesterol Proteins 0.000 description 1
- 230000001071 malnutrition Effects 0.000 description 1
- 235000000824 malnutrition Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 208000015380 nutritional deficiency disease Diseases 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 229940096701 plain lipid modifying drug hmg coa reductase inhibitors Drugs 0.000 description 1
- 239000003531 protein hydrolysate Substances 0.000 description 1
- 238000011552 rat model Methods 0.000 description 1
- 238000007670 refining Methods 0.000 description 1
- 239000012488 sample solution Substances 0.000 description 1
- 229960002855 simvastatin Drugs 0.000 description 1
- RYMZZMVNJRMUDD-HGQWONQESA-N simvastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 RYMZZMVNJRMUDD-HGQWONQESA-N 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 235000021055 solid food Nutrition 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 231100000240 steatosis hepatitis Toxicity 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 238000000825 ultraviolet detection Methods 0.000 description 1
- 229940126673 western medicines Drugs 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/18—Peptides; Protein hydrolysates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Abstract
The invention relates to the field of functional peptides, in particular to antarctic krill hypolipidemic peptide and application thereof in treating hyperlipidemia. The antarctic krill hypolipidemic peptide provided by the invention comprises an amino acid sequence shown in SEQ ID NO. 1 or a variant thereof, and is specifically a nonapeptide compound, wherein the amino acid sequence is as follows: ile-Pro-Ala-Phe-Ser-Gly-Arg-Gly-Trp (IPAFSGRGW) and ESI-MS measured molecular weight of 990.15Da. The hypolipidemic peptide shows remarkable hypolipidemic activity in cell and rat hyperlipidemia models, has the advantages of safety, no toxic or side effect, remarkable hypolipidemic activity and the like, and can be used as hypolipidemic functional molecules to be applied to special medical foods, health care products and medicaments for treating or assisting in treating hyperlipidemia.
Description
Technical Field
The invention relates to the field of functional peptides, in particular to antarctic krill hypolipidemic peptide and application thereof in treating hyperlipidemia.
Background
Hyperlipidemia (HLP), also known as dyslipidemia or dyslipidemia, refers to a systemic lipid metabolism disorder syndrome in which abnormal elevation of lipid metabolism in plasma is accompanied by abnormal changes in lipoprotein cholesterol level due to various pathogenic factors. Wherein, plasma lipids mainly comprise: cholesterol (TC) and Triglycerides (TG); whereas abnormal plasma lipoprotein cholesterol mainly includes: low density lipoprotein cholesterol (LDL-c), high density lipoprotein cholesterol (HDL-c), very low density lipoprotein cholesterol (VLDL-c) and Chylomicron (CM). Hyperlipidemia (HLP) is an important risk factor for cardiovascular and cerebrovascular diseases such as atherosclerosis and coronary heart disease. In addition, hyperlipidemia may also lead to fatty liver, cirrhosis, pancreatitis, hyperuricemia, and the like. Therefore, it is important to research the blood lipid reducing medicine with high efficiency and no toxic and side effect.
The hypolipidemic can improve hyperlipidemia by adjusting TC, TG, LDL-c and HDL-c indexes in serum. At present, western medicines for reducing blood fat, such as HMG-CoA reductase inhibitors (statin drugs), have wide application and obvious curative effect. However, the use of statin drugs is also plagued by toxic and side effects and other factors. For example: cerivastatin (trade name: bayesian) produced by Bayer pharmaceutical factories in Germany has to be taken out of the market for 31 cases of death due to rhabdomyolysis occurring in the United states. Therefore, the development of new drugs for treating hyperlipidemia remains of great importance.
The existing research proves that oligopeptides formed by combining a plurality of amino acids are easier to digest and absorb than amino acids, and amino acids are gradually replaced to become nitrogen sources of special crowd formulas with malnutrition or problems of digestion and absorption. More importantly, compared with amino acid and protein, the oligopeptide shows unique and remarkable biological activity, and the successively discovered antitumor peptide, antioxidant peptide, antihypertensive peptide and the like show great market development prospect.
Based on the method, the applicant designs a new preparation process by taking the antarctic krill protein with rich resources as a raw material and taking the lipid content in a HepG2 cell lipid accumulation model induced by reducing Oleic Acid (OA) as an index, and finds a safe and nontoxic hypolipidemic peptide with remarkable hypolipidemic function, and the hypolipidemic peptide can be applied to special medical foods, health-care products and medicaments for treating or assisting in treating hyperlipidemia.
The foregoing background is intended to assist in understanding the inventive concepts and technical solutions of the present invention and is not necessarily prior art to the present application, but is not intended to be used to evaluate the novelty of the technical solution of the present application in the event that no clear evidence indicates that such disclosure has been published prior to the filing date of the present application.
Disclosure of Invention
In order to solve at least one technical problem mentioned in the background art, one of the purposes of the present invention is to provide a antarctic krill hypolipidemic peptide which shows significant hypolipidemic activity in both cellular and rat hyperlipidemic models.
The second purpose of the invention is to provide an application of the antarctic krill hypolipidemic peptide, wherein the hypolipidemic peptide can be used as hypolipidemic functional molecules to be applied to special medical foods, health-care products and medicines for treating or assisting in treating hyperlipidemia.
In order to achieve the above object, the present invention provides the following technical solutions.
A antarctic krill hypolipidemic peptide comprising the amino acid sequence shown in SEQ ID No. 1 or a variant thereof.
Preferably, the euphausia superba hypolipemic peptide consists of the amino acid sequence shown in SEQ ID NO. 1.
The application takes euphausia superba protein as a raw material, and separates and prepares euphausia superba hypolipidemic peptide which is a nonapeptide compound, and the amino acid sequence of the euphausia superba hypolipidemic peptide is as follows: ile-Pro-Ala-Phe-Ser-Gly-Arg-Gly-Trp (IPAFSGRGW), ESI-MS has a molecular weight of 990.15Da, and the amino acid sequence is shown as SEQ ID NO. 1. According to the results of an induction model test and an animal modeling test, IPAFSGRGW can obviously reduce the contents of lipid, cholesterol (TC) and Triglyceride (TG) in an Oleic Acid (OA) -induced HepG2 cell accumulation model, has the effect of obviously reducing the contents of cholesterol (TC), triglyceride (TG) and low-density lipoprotein cholesterol (LDL-c) in serum of a rat with hyperlipidemia, and IPAFSGRGW can obviously improve the content of high-density lipoprotein cholesterol (HDL-c) in serum of the rat with hyperlipidemia, so that the hypolipidemic peptide IPAFSGRGW can be applied to special medical foods, health-care products and medicines for treating or assisting in treating the hyperlipidemia.
The application of the euphausia superba hypolipidemic peptide comprises the preparation of special medical food and/or health-care product and/or medicine for improving hyperlipidemia by taking the hypolipidemic peptide as an effective component.
Preferably, the ameliorating hyperlipidemia includes at least one of preventing, treating, and adjunctively treating hyperlipidemia.
Preferably, the improvement comprises reducing the content of lipids, cholesterol and triglycerides in an oleic acid induced HepG2 cell accumulation model.
Preferably, the improvement comprises reducing the cholesterol, triglyceride, low density lipoprotein cholesterol levels in the serum of hyperlipidemic rats.
Preferably, the improvement comprises increasing the content of high density lipoprotein cholesterol in the serum of the hyperlipidemic rat.
Preferably, the biomedical food and/or health food is at least one of a solid food or a liquid beverage.
Preferably, the medicament is at least one of a liquid dosage form or a lyophilized powder.
A medicament for treating hyperlipidemia, which comprises an effective amount of the euphausia superba hypolipidemic peptide and a pharmaceutically acceptable carrier.
The weight percentage of the antarctic krill hypolipemic peptide in the medicine is 0.01-99.99%.
The weight percentage of the antarctic krill hypolipemic peptide in the medicine is 1.0-55%.
The antarctic krill hypolipemic peptide in the medicament is the only or main effective component in the medicament.
The above-mentioned preferable conditions can be combined with each other to obtain a specific embodiment on the basis of common knowledge in the art.
The raw materials or the reagents involved in the invention are all common commercial products, and the related operations are all routine operations in the field unless specified.
Compared with the prior art, the antarctic krill hypolipemic peptide Ile-Pro-Ala-Phe-Ser-Gly-Arg-Gly-Trp (IPAFSGRGW) provided by the invention can obviously reduce the contents of lipid, total Cholesterol (TC) and Triglyceride (TG) in an Oleic Acid (OA) -induced HepG2 cell lipid accumulation model, obviously reduce TC, TG and LDL-c in experimental hyperlipidemia rat serum, and raise HDL-c. IPAFSGRGW has the advantages of safety, no toxic or side effect, remarkable hypolipidemic activity and the like, and can be applied to special medical foods, health products and medicaments for treating or assisting in treating hyperlipidemia.
The invention adopts the technical proposal to realize the aim, makes up the defects of the prior art, has reasonable design and convenient operation.
Drawings
The foregoing and/or other objects, features, advantages and embodiments of the invention will be apparent from the following description taken in conjunction with the accompanying drawings in which:
FIG. 1 is a Sephadex LH-20 chromatographic chart of NPH-I-1;
FIG. 2 is an RP-HPLC analysis of NPH-I-1c;
FIG. 3 is a structural formula of a antarctic krill hypolipemic peptide;
FIG. 4 is a mass spectrum of the antarctic krill hypolipemic peptide;
FIG. 5 is a schematic representation of the effect of antarctic krill hypolipidemic peptide on Triglyceride (TG) content in an Oleic Acid (OA) -induced HepG2 cell lipid accumulation model;
FIG. 6 is a schematic representation of the effect of antarctic krill hypolipemic peptide on cholesterol (TC) content in an Oleic Acid (OA) -induced HepG2 cell lipid accumulation model;
FIG. 7 is a schematic diagram showing the effect of antarctic krill hypolipidemic peptide on serum Triglyceride (TG) content in experimental hyperlipidemic rats;
FIG. 8 is a schematic representation of the effect of antarctic krill hypolipidemic peptide on serum cholesterol (TC) levels in experimental hyperlipidemic rats;
FIG. 9 is a schematic representation of the effect of antarctic krill hypolipidemic peptide on serum low density lipoprotein cholesterol (LDL-c) levels in experimental hyperlipidemic rats;
FIG. 10 is a schematic diagram showing the effect of antarctic krill hypolipidemic peptide on serum high density lipoprotein cholesterol (HDL-c) levels in experimental hyperlipidemic rats.
Detailed Description
Suitable substitutions and/or modifications of the process parameters will be apparent to those skilled in the art from the disclosure herein, however, it is to be expressly pointed out that all such substitutions and/or modifications are intended to be encompassed by the present invention. While the products and methods of preparation of the present invention have been described in terms of preferred embodiments, it will be apparent to those skilled in the relevant art that variations and modifications can be made in the products and methods of preparation described herein without departing from the spirit and scope of the invention.
Unless defined otherwise, technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. The present invention uses the methods and materials described herein; other suitable methods and materials known in the art may be used. The materials, methods, and examples described herein are illustrative only and not intended to be limiting. All publications, patent applications, patents, provisional applications, database entries, and other references mentioned herein, and the like, are incorporated herein by reference in their entirety. In case of conflict, the present specification, including definitions, will control.
All percentages, parts, ratios, etc., are by weight unless otherwise specified; the other specification includes, but is not limited to, "wt%" means weight percent, "mol%" means mole percent, "vol%" means volume percent.
When an amount, concentration, or other value or parameter is given as either a range, preferred range, or a series of upper preferable values and lower preferable values, this is to be understood as specifically disclosing all ranges formed from any pair of any upper range limit or preferred value and any lower range limit or preferred value, regardless of whether ranges are separately disclosed. For example, when a range of "1 to 5 (1 to 5)" is described, the described range should be understood to include ranges of "1 to 4 (1 to 4)", "1 to 3 (1 to 3)", "1 to 2 (1 to 2) and 4 to 5 (4 to 5)", "1 to 3 (1 to 3) and 5", and the like. Where a range of values is described herein, unless otherwise stated, the range includes the range endpoints and all integers and fractions within the range.
Unless specifically stated otherwise, the materials, methods, and examples described herein are illustrative only and not intended to be limiting. Although methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present invention, suitable methods and materials are described herein.
It should be known in the art that the amino acid sequence of the antarctic krill hypolipidemic peptide provided by the invention is Ile-Pro-Ala-Phe-Ser-Gly-Arg-Gly-Trp, abbreviated as IPAFSGRGW, wherein Ile corresponds to I, i.e. isoleucine; pro corresponds to P, i.e., proline; ala corresponds to A, and alanine; phe corresponds to F, phenylalanine; ser corresponds to S, serine; gly corresponds to G, namely ammonium glycoside; arg corresponds to R, arginine; trp corresponds to W, tryptophan.
It should be understood in the art that OA is oleic acid, TC is total cholesterol, TG is triglyceride, LDL-c is low density lipoprotein cholesterol, HDL-c is high density lipoprotein cholesterol.
The invention provides antarctic krill hypolipidemic peptide which is a nonapeptide compound, and the amino acid sequence of the antarctic krill hypolipidemic peptide is as follows: ile-Pro-Ala-Phe-Ser-Gly-Arg-Gly-Trp (IPAFSGRGW), the amino acid sequence table is shown as SEQ ID NO. 1, and the molecular weight measured by ESI-MS is 990.15Da.
The invention also provides a preparation method of the antarctic krill hypolipidemic peptide, which comprises the following steps: pretreatment, enzymolysis, separation and extraction, specifically comprising:
1) Pretreatment: removing heads and shells of euphausia superba, cleaning, homogenizing to paste, adding absolute ethyl alcohol according to a feed-liquid ratio of 1g to 5-8 mL, performing 500W ultrasonic degreasing for 30-60 min, filtering, repeating the above operation for 2 times, and thoroughly removing lipid in euphausia superba; drying and filtering the obtained solid to obtain defatted euphausia superba powder;
2) Enzymolysis: adding buffer solution into defatted antarctic krill powder according to the feed-liquid ratio of 1 g:5-8 mL, regulating pH value to 1.5-2.5, adding pepsin with 2-3% of the weight of the shrimp powder (enzyme activity is more than or equal to 3.0X10) 4 U/g), enzymatic hydrolysis is carried out for 3 to 4 hours at the temperature of 35 to 40 ℃, enzyme is inactivated for 10 to 15 minutes at the temperature of 90 to 100 ℃, the temperature is cooled to 45 to 50 ℃, the pH value is regulated to 6.5 to 8.0, and neutral protease with the weight of 1.5 to 2.5 percent of the shrimp meal (the enzyme activity is more than or equal to 1.0 multiplied by 10) is added 5 U/g), enzymatic hydrolysis for 3-4 h, enzyme deactivation at 90-100 ℃ for 10-15 min, centrifugation at 6000-9000 rmp for 25-30 min, collection and collectionClear liquid is obtained to obtain euphausia superba enzymolysis liquid; the euphausia superba polypeptide is obtained by using a double-enzyme composite enzymolysis technology, and no toxic or side organic solvent is added, so that the safety is high, the preparation cost is low, and the reaction condition is mild; pepsin and neutral protease can quickly degrade defatted euphausia superba powder into small-molecule high-activity oligopeptides, and the yield is high;
3) Separating and extracting: grading the euphausia superba proteolysis solution by an ultrafiltration membrane with a molecular weight cutoff of 3kDa, collecting grading components, determining lipid reduction capacity (expressed by a% blank group) of each component in an Oleic Acid (OA) -induced HepG2 cell lipid accumulation model, and sequentially enriching the ultrafiltration component with the strongest lipid reduction capacity by macroporous resin, performing gel chromatography and reversed-phase high-performance liquid chromatography (RP-HPLC purification) to obtain euphausia superba lipid-lowering peptide.
The specific processes of macroporous resin enrichment, gel chromatography and RP-HPLC purification in the separation and extraction step are as follows:
enriching with macroporous resin: dissolving the ultrafiltration component with the strongest lipid-lowering capacity in double distilled water to prepare a solution with the concentration of 90-100 mg/mL, slowly adding the sample solution into a resin column according to the ratio of 1g to 10-20 g of sample to D101 macroporous resin, and washing the resin column by double distillation with the volume of 2-3 times of the column volume to remove unadsorbed samples; washing the resin column with 2-3 times of 60% ethanol, collecting the eluting solution, and freeze-drying to obtain an enriched sample;
gel column chromatography: dissolving a D101 macroporous resin enriched sample in double distilled water to prepare a solution with the concentration of 40-50 mg/mL, separating by Sephadex LH-20 column chromatography (2.5 cm multiplied by 160 cm), eluting by double distilled water at the flow rate of 0.5-0.8 mL/min, collecting chromatographic peaks according to a 214nm chromatogram, and determining the lipid-lowering capacity of each chromatographic peak, wherein the highest active chromatographic peak is gel chromatographic zymolyte;
RP-HPLC purification: preparing the gel chromatography zymolyte into a solution with the concentration of 25-30 mug/mL by double distilled water, purifying by RP-HPLC, obtaining 1 high-activity hypolipidemic peptide Ile-Pro-Ala-Phe-Ser-Gly-Arg-Gly-Trp (IPAFSGRGW) according to hypolipidemic activity of the prepared oligopeptide, and measuring the molecular weight of 990.15Da by ESI-MS.
The conditions for the RP-HPLC purification are as follows: the sample injection amount is 15-20 mu L; chromatographic column Kromasil C-18 (250 mm. Times.4.6 mm,5 μm); mobile phase: the acetonitrile concentration is increased from 0 to 100 percent at a constant speed within 0 to 30 minutes; the elution speed is 0.6-0.8 mL/min; the ultraviolet detection wavelength is 214nm.
The present invention is described in detail below.
Example 1:
the embodiment provides a antarctic krill hypolipidemic peptide, which is a nonapeptide compound, and the amino acid sequence of the hypolipidemic peptide is as follows: ile-Pro-Ala-Phe-Ser-Gly-Arg-Gly-Trp (IPAFSGRGW), ESI-MS has a molecular weight of 990.15Da, and the amino acid sequence is shown as SEQ ID NO. 1.
The preparation method of the antarctic krill hypolipidemic peptide provided by the embodiment comprises the following steps:
1) Pretreatment: removing heads and shells of antarctic krill, cleaning, homogenizing to paste, adding absolute ethyl alcohol according to a feed-liquid ratio of 1g to 6mL, performing 500W ultrasonic degreasing for 45min, filtering, repeating the above operation for 2 times, and removing lipid in antarctic krill; drying and filtering the obtained solid to obtain defatted euphausia superba powder;
2) Enzymolysis: adding buffer solution into defatted Euphausia superba powder at a ratio of 1 g/8 mL, adjusting pH to 2.5, and adding pepsin (enzyme activity 3.0X10:3% of shrimp powder weight) 4 U/g), performing enzymolysis at 37deg.C for 4 hr, inactivating enzyme at 95deg.C for 10min, cooling to 50deg.C, adjusting pH to 7.0, adding neutral protease (enzyme activity 1.0X10) accounting for 2.0% of shrimp meal weight 5 U/g), performing enzymolysis for 4 hours, inactivating enzyme at 95 ℃ for 15 minutes, centrifuging at 9000rmp for 25 minutes, and collecting supernatant to obtain euphausia superba enzymolysis liquid (NPH);
3) Separating and extracting: grading the euphausia superba proteolysis solution (NPH) by an ultrafiltration membrane with a cut-off molecular weight of 3kDa, collecting grading components NPH-I (MW less than or equal to 3 kDa) and NPH-II (MW more than 3 kDa), determining a HepG2 cell lipid accumulation model induced by the NPH-I and the NPH-II on Oleic Acid (OA) (model building method is referred to [ Pan Xin ], the preparation of the squid meat and the swim bladder functional polypeptide and the oxidation resistance and lipid reduction activity research [ D ] the ocean university of Zhejiang, 2017 ]) and sequentially carrying out macroporous resin enrichment, gel chromatography and reversed-phase high performance liquid chromatography (RP-HPLC) purification on the NPH-I with the strongest lipid reduction capacity to obtain euphausia superba hypolipemic peptide, and determining the structure by using an amino acid sequence analyzer and mass spectrum, wherein the specific process is as follows:
(1) enriching with macroporous resin: dissolving NPH-I in double distilled water to prepare a solution with the concentration of 100mg/mL, slowly adding the NPH-I solution into a resin column according to the proportion of NPH-I to D101 macroporous resin 1g:15g, and washing the resin column by double distillation with the volume of 3 times of the column volume to remove the NPH-I solution to obtain an adsorption sample; washing the resin column with 3 times of 60% ethanol, collecting the eluting solution, lyophilizing to obtain enriched sample (NPH-I-1), and determining NPH-I-1 lipid-lowering ability (see Table 1);
(2) gel chromatography: dissolving NPH-I-1 in double distilled water to prepare a solution with the concentration of 50mg/mL, separating by Sephadex LH-20 column chromatography (2.5 cm multiplied by 160 cm), eluting by double distilled water at the flow rate of 0.5mL/min, collecting each chromatographic peak NPH-I-1 a-NPH-I-1 c according to a 214nm chromatogram, determining the hypolipidemic capacity of each chromatographic peak (see Table 1), wherein the highest active chromatographic peak is gel chromatography zymolyte NPH-I-1c;
(3) refining by RP-HPLC and detecting the structure: preparing the gel chromatography zymolyte NPH-I-1C into a solution with the concentration of 30 mug/mL by double distilled water, purifying by RP-HPLC, wherein the sample injection amount is 20 mug, and the chromatographic column Kromasil C-18 (250 mm multiplied by 4.6mm,5 mu m; the acetonitrile concentration of the mobile phase is uniformly increased from 0 to 100% in 0-30 min) and the elution speed is 0.8mL/min; collecting active peptides NJP-1-NJP-7 according to 214nm chromatographic peaks, and obtaining 1 high-activity lipid-lowering peptide NJP-3 according to the lipid-lowering activity (see Table 1) of the oligopeptides NJP-1-NJP-7 shown in FIG. 2; the amino acid sequence is Ile-Pro-Ala-Phe-Ser-Gly-Arg-Gly-Trp (IPAFSGRGW), the structural formula is shown in figure 3, and the molecular weight is 990.15Da by ESI-MS, which is shown in figure 4. Table 1 effect of antarctic krill protein hydrolysate, separation fractions and preparation of active peptides on lipid content in Oleic Acid (OA) -induced HepG2 cell lipid accumulation model (n=3)
Example 2:
based on the foregoing examples, this example demonstrates the effect of antarctic krill hypolipidemic peptide on Oleic Acid (OA) -induced content of Triglyceride (TG) and cholesterol (TC) in HepG2 cell lipid accumulation model, specifically comprising:
and (3) building a model: referring to the prior art [ Pan Xin ] preparation of functional polypeptides of the fish meat and swim bladder of the Miichthys miiuy, antioxidant and lipid lowering activity research [ D ] university of ocean in Zhejiang, 2017] to establish an Oleic Acid (OA) -induced HepG2 cell lipid accumulation model;
analysis of results: the effects of IPAFSGRGW on triglyceride and cholesterol in an Oleic Acid (OA) -induced HepG2 cell lipid accumulation model are shown in fig. 5 and 6, respectively, and as can be seen from fig. 5 and 6, the antarctic krill hypolipemic peptides IPAFSGRGW in the application have remarkable inhibitory effects on TG and TC in an Oleic Acid (OA) -induced HepG2 cell lipid accumulation model, and the inhibitory effects are close to that of simvastatin, a positive drug.
Example 3:
based on the foregoing examples, in vivo experiments in rats with hyperlipidemia were performed in this example, and the effects of antarctic krill hypolipidemic peptide on the same were verified, specifically including:
and (3) building a model: referring to the prior art [ Chen Bei ] the lipid regulating effect of the basil extract on the hyperlipidemia rats and the mechanism research [ D ] the university of Xinjiang medical science, 2009] to establish an experimental hyperlipidemia rat model;
analysis of results: effects of IPAFSGRGW on TG, TC, LDL-c and HDL-c in serum of hyperlipidemic rats As shown in FIGS. 7 to 10, respectively, LPGTRIPA was found to significantly reduce the levels of TG, TC and LDL-c and increase the levels of HDL-c in serum of experimental hyperlipidemic rats.
In conclusion, ile-Pro-Ala-Phe-Ser-Gly-Arg-Gly-Trp (IPAFSGRGW) obviously reduces the blood lipid level in cells and animal models, is safe and has no toxic or side effect, and can be applied to special medical foods, health care products and medicaments for treating or assisting in treating hyperlipidemia.
The conventional technology in the above embodiments is known to those skilled in the art, and thus is not described in detail herein.
The specific embodiments described herein are offered by way of example only to illustrate the spirit of the invention. Various modifications or additions to the described embodiments may be made by those skilled in the art to which the invention pertains or may be substituted in a similar manner without departing from the spirit of the invention or beyond the scope of the appended claims.
Finally, it should be noted that the above list is only one embodiment of the present invention. Obviously, the invention is not limited to the above embodiments, but many variations are possible. All modifications directly derived or suggested to one skilled in the art from the present disclosure should be considered as being within the scope of the present invention.
The invention is a well-known technique.
Claims (10)
1. A euphausia superba hypolipidemic peptide is an amino acid sequence shown in SEQ ID NO. 1.
2. The antarctic krill hypolipidemic peptide of claim 1, wherein: the antarctic krill hypolipemic peptide consists of an amino acid sequence shown in SEQ ID NO. 1.
3. The use of the antarctic krill hypolipidemic peptide according to claim 1 or 2, characterized by comprising the preparation of a medicament for ameliorating hyperlipidemia with the hypolipidemic peptide as an effective ingredient.
4. A use according to claim 3, characterized in that: the improvement of hyperlipidemia includes at least one of prevention, treatment and adjuvant therapy of hyperlipidemia.
5. Use according to claim 3 or 4, characterized in that: the improvement
Comprising reducing the lipid, cholesterol and triglyceride levels in an oleic acid-induced HepG2 cell accumulation model; and/or
Comprises reducing the content of cholesterol, triglyceride and low-density lipoprotein cholesterol in the serum of the rat with hyperlipidemia; and/or
Comprises increasing the content of high density lipoprotein cholesterol in the serum of the rat suffering from hyperlipidemia.
6. Use according to claim 3 or 4, characterized in that:
the medicament is at least one of a liquid dosage form or a lyophilized powder.
7. A medicament for preventing or treating hyperlipidemia, which is characterized by comprising an effective amount of the antarctic krill hypolipidemic peptide of claim 1 or 2 and a pharmaceutically acceptable carrier.
8. A medicament according to claim 7, characterized in that: the weight percentage of the antarctic krill hypolipemic peptide in the medicine is 0.01-99.99%.
9. A medicament according to claim 7 or 8, characterized in that: the weight percentage of the antarctic krill hypolipemic peptide in the medicine is 1.0-55%.
10. A medicament according to claim 7 or 8, characterized in that: the antarctic krill hypolipemic peptide in the medicament is the only or main effective component in the medicament.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111011432.9A CN113698453B (en) | 2021-08-31 | 2021-08-31 | Antarctic krill hypolipidemic peptide and application thereof in treating hyperlipidemia |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111011432.9A CN113698453B (en) | 2021-08-31 | 2021-08-31 | Antarctic krill hypolipidemic peptide and application thereof in treating hyperlipidemia |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN113698453A CN113698453A (en) | 2021-11-26 |
| CN113698453B true CN113698453B (en) | 2023-04-25 |
Family
ID=78657904
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202111011432.9A Active CN113698453B (en) | 2021-08-31 | 2021-08-31 | Antarctic krill hypolipidemic peptide and application thereof in treating hyperlipidemia |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN113698453B (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115843993A (en) * | 2022-11-08 | 2023-03-28 | 浙江工业大学 | Umami peptide and preparation method and application thereof |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107095312A (en) * | 2017-03-30 | 2017-08-29 | 大连大学 | A kind of krill polypeptide formulations with reducing blood lipid ability and preparation method thereof |
| CN109400674A (en) * | 2018-11-22 | 2019-03-01 | 浙江海洋大学 | Antihypertensive tripeptide derived from euphausia superba and application thereof |
-
2021
- 2021-08-31 CN CN202111011432.9A patent/CN113698453B/en active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107095312A (en) * | 2017-03-30 | 2017-08-29 | 大连大学 | A kind of krill polypeptide formulations with reducing blood lipid ability and preparation method thereof |
| CN109400674A (en) * | 2018-11-22 | 2019-03-01 | 浙江海洋大学 | Antihypertensive tripeptide derived from euphausia superba and application thereof |
Non-Patent Citations (2)
| Title |
|---|
| Bodil Bjørndal et al.Krill powder increases liver lipid catabolism and reduces glucose mobilization in tumor necrosis factor-alpha transgenic mice fed a high-fat diet.Metabolism.2012,61(10),1461-1672. * |
| 王亚恩 ; 姜国良 ; 徐恺 ; 赵传凯 ; 李立德 ; 刘云 ; .南极磷虾油对高脂血症大鼠血脂和抗氧化力的影响.中国海洋药物.2011,(03),全文. * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN113698453A (en) | 2021-11-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US8940685B2 (en) | Method for preparing active peptides from corn germ proteins | |
| CN107163129B (en) | Preparation and application of kappa-casein-derived bioactive peptide | |
| Mohamad Ansor et al. | Anti-angiotensin converting enzyme (ACE) proteins from mycelia of Ganoderma lucidum (Curtis) P. Karst | |
| CN106632605B (en) | Active peptide prepared from tuna leftovers and having liver injury repair effect | |
| Ko et al. | Effect of angiotensin I-converting enzyme (ACE) inhibitory peptide purified from enzymatic hydrolysates of Styela plicata | |
| CN107573406B (en) | Urechis unicinctus bioactive peptide and preparation method thereof | |
| CN113698453B (en) | Antarctic krill hypolipidemic peptide and application thereof in treating hyperlipidemia | |
| CN111518164B (en) | ACE inhibitory peptide P2, application thereof and preparation method thereof | |
| KR101170998B1 (en) | Glycoprotein fraction isolated from rice bran and method for producing the same | |
| JPH0920672A (en) | Antiallergic substance, its production, antiallergic agent and functional food | |
| CN113087773B (en) | Yak bone peptide with blood sugar reducing and antioxidant functions and preparation method thereof | |
| CN116751247A (en) | Tuna heart arteria artery bulb antioxidant peptide with liver protection effect, and preparation method and application thereof | |
| CN102787154B (en) | Preparation method of black-bone chicken oligopeptide and separation and identification method of active peptide fragment | |
| CN114044807B (en) | Mussel hypolipidemic oligopeptide for treating hyperlipidemia | |
| CN111499691B (en) | ACE inhibitory peptide P1, application thereof and preparation method thereof | |
| CN108047325A (en) | A kind of reducing blood lipid pentapeptide for coming from the brown croaker flesh of fish and its application | |
| CN105175495B (en) | Application of defatted crab shell antioxidant peptide | |
| KR101497506B1 (en) | The Pharmaceutical composition and functional food for inhibiting angiotensin-I converting enzyme | |
| WO2011112099A1 (en) | Peptide material, and preparations and uses thereof | |
| CN112442112A (en) | Ginkgo protein source ACE inhibitory peptide composition and preparation method and application thereof | |
| Kan et al. | Hypolipidemic effect of proteoglycans isolated from sweet potato (Ipomoea batatas LAM) in hyperlipidemia rats | |
| JP2003038158A (en) | Purified concentrate having inhibitory action on crisis of hepatopathy collected from distillation residual liquid of barley shochu (japanese distilled spirit) and method for producing the same | |
| CN113730549B (en) | Application of milk-derived active peptide CCL-1S in preparation of sleep-promoting product | |
| WO2011112100A1 (en) | Peptide material, feed composition and preparations and uses thereof | |
| CN111004305B (en) | Agaricus blazei murill small peptide and preparation method and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| TR01 | Transfer of patent right | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20230614 Address after: 410600 lanyuegu Road, Ningxiang Economic and Technological Development Zone, Changsha City, Hunan Province (702, building 2, xiangjinyi Industrial Park) Patentee after: Hunan Yibai Yiyou Biotechnology Co.,Ltd. Address before: 710000 No. B49, Xinda Zhongchuang space, 26th Street, block C, No. 2 Trading Plaza, South China City, international port district, Xi'an, Shaanxi Province Patentee before: Xi'an Huaqi Zhongxin Technology Development Co.,Ltd. Effective date of registration: 20230614 Address after: 710000 No. B49, Xinda Zhongchuang space, 26th Street, block C, No. 2 Trading Plaza, South China City, international port district, Xi'an, Shaanxi Province Patentee after: Xi'an Huaqi Zhongxin Technology Development Co.,Ltd. Address before: 316002 No.1 Haida South Road, Changzhi Island, Lincheng street, Dinghai District, Zhoushan City, Zhejiang Province Patentee before: Zhejiang Ocean University |